| Autores |
Younossi, Zobair M. , Alqahtani, Saleh A. , Alswat, Khalid , Yilmaz, Yusuf , Keklikkiran, Caglayan , FUNUYET SALAS, JESÚS, Romero-Gomez, Manuel , Fan, Jian-Gao , Zheng, Ming-Hua , El-Kassas, Mohamed , Castera, Laurent , Liu, Chun-Jen , Wong, Vincent Wai-Sun , Zelber-Sagi, Shira , Allen, Alina M. , Lam, Brian , Treeprasertsuk, Sombat , Hameed, Saeed , Takahashi, Hirokazu , Kawaguchi, Takumi , Schattenberg, Joern M. , Duseja, Ajay , Newsome, Phil N. , Francque, Sven , Spearman, C. Wendy , Fernandez, Marlen I. Castellanos , Burra, Patrizia , Roberts, Stuart K. , Chan, Wah-Kheong , Arrese, Marco , Silva, Marcelo , Rinella, Mary , Singal, Ashwani K. , Gordon, Stuart , Fuchs, Michael , Alkhouri, Naim , Cusi, Kenneth , Loomba, Rohit , Ranagan, Jane , Eskridge, Wayne , Kautz, Achim , Ong, Janus P. , Kugelmas, Marcelo , Eguchi, Yuichiro , Diago, Moises , Yu, Ming-Lung , Gerber, Lynn , Fornaresio, Lisa , Nader, Fatema , Henry, Linda , Racila, Andrei , Golabi, Pegah , Stepanova, Maria , Carrieri, Patrizia , Lazarus, Jeffrey , Global Nash Council |
| Abstract |
Background & Aims: Patients with fatty liver disease may experience stigma from the disease or comorbidities. In this cross-sectional study, we aimed to understand stigma among patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) and healthcare providers. Methods: Members of the Global NASH Council created two surveys about experiences/attitudes toward NAFLD and related diagnostic terms: a 68-item patient and a 41-item provider survey. Results: Surveys were completed by 1,976 patients with NAFLD across 23 countries (51% Middle East/North Africa [MENA], 19% Europe, 17% USA, 8% Southeast Asia, 5% South Asia) and 825 healthcare providers (67% gastroenterologists/hepatologists) across 25 countries (39% MENA, 28% Southeast Asia, 22% USA, 6% South Asia, 3% Europe). Of all patients, 48% ever disclosed having NAFLD/NASH to family/friends; the most commonly used term was "fatty liver" (88% at least sometimes); "metabolic disease" or "MAFLD" were rarely used (never by >84%). Regarding various perceptions of diagnostic terms by patients, there were no substantial differences between "NAFLD", "fatty liver disease (FLD)", "NASH", or "MAFLD". The most popular response was being neither comfortable nor uncomfortable with either term (56%-71%), with slightly greater discomfort with "FLD" among the US and South Asian patients (47-52% uncomfortable). Although 26% of patients reported stigma related to overweight/obesity, only 8% reported a history of stigmatization or discrimination due to NAFLD. Among providers, 38% believed that the term "fatty" was stigmatizing, while 34% believed that "nonalcoholic" was stigmatizing, more commonly in MENA (43%); 42% providers (gastroenterologists/hepatologists 45% vs. 37% other specialties, p = 0.03) believed that the name change to metabolic dysfunction-associated steatotic liver disease (or MASLD) might reduce stigma. Regarding the new nomenclature, the percentage of providers reporting "steatotic liver disease" as stigmatizing was low (14%). Conclusions: The perception of NAFLD stigma varies among patients, providers, geographic locations and sub-specialties. (c) 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. |
Gestionar cookies